InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.018 -0.064 (-78.05%)+
Announcement
Release
30 Oct 2025 8:38AM
Price at Release
$0.082
Full Release
download
Summary
CurveBeam AI Limited reported its quarterly activities and Appendix 4C cash flow for the period ending 30 September 2025. The company received purchase orders for four devices, including three HiRise™ units, marking a 33.3% growth compared to the previous year. CurveBeam AI successfully completed a placement raising A$6.5 million and entered into a significant partnership with a Chinese distributor, ensuring exclusive distribution rights in several territories. The company's efforts towards FDA clearance for its BMD MDCT software module continue, with a target of mid-2026. Additionally, CurveBeam AI signed a vendor financing agreement for approximately A$18 million. Despite a decrease in cash from operations due to seasonal factors, the company maintains a positive outlook with future funding anticipated from strategic partnerships.
Key Points
  • Purchase orders increased by 33.3% in Q1 FY26.
  • Raised A$6.5 million through a share placement.
  • Entered a 10-year distribution agreement in China.
  • FDA clearance targeted for mid-2026 for BMD MDCT software.
  • Established a vendor financing facility of A$18 million.
  • Cash from operations decreased due to seasonal factors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.